A new slow-release implant has shown unprecedented success in wiping out bladder cancer in more than 80 percent of patients, ...

Patients with initially low- or intermediate-risk primary tumors will often have a high-risk recurrence before progressing to more advanced disease, whereas primary high-risk tumors typically show ...

ESMO 2025 bladder cancer highlights include results from KEYNOTE-905/EV-303, RC48-C016, and IMvigor011 studies.

On Thursday, Aura Biosciences, Inc. (NASDAQ:AURA) revealed early data from an ongoing Phase 1 trial of bel-sar (AU-011) in patients with non-muscle-invasive bladder cancer (NMIBC). To date, the trial ...

Imagine a targeted approach to bladder cancer that spares healthy cells while delivering chemotherapy directly to cancerous ...

Bladder cancer ranks among the ten most common types of cancer worldwide. The main treatment is bladder removal surgery, and ...

Growth hormone receptor (GHR) signaling in bladder cancer is associated with advanced tumor stages and poor survival outcomes. High GHR expression in tumors up-regulates genes involved in drug ...

The IMvigor010 trial showed that Signatera-guided treatment with Tecentriq improved disease-free survival and overall ...

A new study has identified a protein that helps drive bladder cancer by triggering the synthesis of cholesterol via mouse and cell models. Researchers found that a combination therapy of two drugs ...

DENVER (KDVR) — The University of Colorado Buffaloes head coach Deion Sanders said on Monday that he was absent from coaching because he had his bladder removed after doctors found a tumor. Sanders ...

TAR-200, a small drug-releasing implant, wiped out tumors in most patients with high-risk bladder cancer. Its slow, ...